The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antirevmatika škodlivé účinky metabolismus terapeutické užití MeSH
- dospělí MeSH
- farmakogenetika MeSH
- fenotyp MeSH
- heterozygot MeSH
- homozygot MeSH
- jednonukleotidový polymorfismus * MeSH
- lidé středního věku MeSH
- lidé MeSH
- lineární modely MeSH
- logistické modely MeSH
- methotrexát škodlivé účinky metabolismus terapeutické užití MeSH
- methylentetrahydrofolátreduktasa (NADPH2) genetika metabolismus MeSH
- odds ratio MeSH
- polymerázová řetězová reakce MeSH
- prospektivní studie MeSH
- průřezové studie MeSH
- retrospektivní studie MeSH
- revmatoidní artritida diagnóza farmakoterapie enzymologie genetika MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antirevmatika MeSH
- methotrexát MeSH
- methylentetrahydrofolátreduktasa (NADPH2) MeSH
- MTHFR protein, human MeSH Prohlížeč
Some single-nucleotide polymorphisms (SNPs) might be predictive of methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA). The aim of this study was to determine whether SNPs in the methylenetetrahydrofolate reductase (MTHFR) gene are predictive of MTX response. Comparison was made using EULAR response criteria and according to the change of DAS28 (∆DAS28) after a 6-month MTX treatment in RA patient cohort. The two SNPs C677T (rs1801133) and A1298C (rs1801131) have been genotyped. A total of 120 patients were enrolled in the study, and all of them fulfilled the American College of Rheumatology 1987 RA criteria and are currently or previously taking MTX oral treatment, either as a monotherapy (n = 65) or in a combination with other disease-modifying antirheumatic drugs (n = 55). Genotyping was performed using qPCR allelic discrimination. We did not found any association of C677T and A1298C genotypes with MTX treatment inefficacy in dominant model (OR 1.23, 95 % CI 0.57-2.65, P = 0.697; and OR 0.98, 95 % CI 0.47-2.14, P = 1.0, respectively), or in recessive and codominant models. However, when ∆DAS28 after a 6-month therapy was used as a measure of treatment efficacy, the 677CT and 1298AC genotypes were found to be significantly associated with less favorable response to MTX (P = 0.025 and P = 0.043, respectively). In addition, even lower ∆DAS28 was determined for double-mutated 677CT-1298AC heterozygotes. It means that a synergistic effect of 677CT and 1298AC genotypes was observed. Nevertheless, the DAS28 baseline was lower here comparing to other genotypes. Unexpectedly, quite the opposite trend-i.e., better response to MTX-was found in genotypes 677CC-1298CC and 677TT-1298AA. It is an intriguing finding, because these double-mutated homozygotes are known for their low MTHFR-specific activity. Global significance was P = 0.013, η (2) = 0.160-i.e., large-size effect. Thus, our data show greater ability of 677CC-1298CC and 677TT-1298AA genotypes to respond to MTX treatment.
Zobrazit více v PubMed
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S179-85 PubMed
Ann Rheum Dis. 2013 Jan;72 (1):64-71 PubMed
Ann Rheum Dis. 2014 Jul;73(7):1356-61 PubMed
Am J Hum Genet. 2000 Oct;67(4):986-90 PubMed
Clin Rheumatol. 2007 Feb;26(2):201-4 PubMed
Arthritis Rheum. 2006 Jan;54(1):26-37 PubMed
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S33-9 PubMed
Birth Defects Res A Clin Mol Teratol. 2013 Jul;97(7):444-51 PubMed
Am J Hum Genet. 1998 May;62(5):1044-51 PubMed
Arthritis Rheum. 2008 Sep;58(9):2622-31 PubMed
Br J Nutr. 2000 Jun;83(6):593-6 PubMed
Pharmacogenomics. 2010 Feb;11(2):163-75 PubMed
Clin Rheumatol. 2014 Dec;33(12):1715-24 PubMed
Pharmacogenet Genomics. 2012 Feb;22(2):117-33 PubMed
Ann Rheum Dis. 2009 Jul;68(7):1094-9 PubMed
Interv Med Appl Sci. 2013 Mar;5(1):46-51 PubMed
Rheumatol Int. 2012 Jun;32(6):1837-42 PubMed
Ann Rheum Dis. 2009 Dec;68(12 ):1870-7 PubMed
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):861-6 PubMed
Rheum Dis Clin North Am. 2006 Feb;32(1):9-44, vii PubMed
J Stroke Cerebrovasc Dis. 2013 May;22(4):465-9 PubMed
Nat Genet. 1995 May;10(1):111-3 PubMed
Pharmacol Rev. 2005 Jun;57(2):163-72 PubMed
Curr Pharm Des. 2010;16(2):164-75 PubMed
Biomed Res Int. 2014;2014:368681 PubMed
Curr Drug Metab. 2009 Jul;10(6):547-66 PubMed
Arthritis Rheum. 2004 Nov;50(11):3432-43 PubMed
Ann Rheum Dis. 2014 Mar;73(3):492-509 PubMed
Pharmacogenomics J. 2013 Apr;13(2):137-47 PubMed
Lancet. 2004 Feb 28;363(9410):675-81 PubMed
Genet Mol Res. 2013 Oct 29;12(4):5160-71 PubMed
Cancer Res. 2005 Apr 1;65(7):2577-82 PubMed
Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S5-8 PubMed
Ann Rheum Dis. 2009 Jul;68(7):1100-4 PubMed
Lancet. 1999 May 8;353(9164):1568-73 PubMed
Pharmacogenomics. 2014 Mar;15(4):467-75 PubMed
J Rheumatol. 2002 Aug;29(8):1631-8 PubMed
Dement Geriatr Cogn Disord. 2011;32(3):159-63 PubMed
Clin Drug Investig. 2010;30(2):101-8 PubMed
Pharmacogenomics. 2014 Jun;15(8):1079-90 PubMed
Ann Rheum Dis. 2014 Mar;73(3):510-5 PubMed
Arthritis Rheum. 1996 Jan;39(1):34-40 PubMed
Ann Rheum Dis. 2000 Nov;59 Suppl 1:i28-31 PubMed
Arthritis Rheum. 2007 Jun;56(6):1765-75 PubMed
J Rheumatol. 2009 Mar;36(3):539-45 PubMed
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14853-8 PubMed
Am J Reprod Immunol. 2012 Mar;67(3):251-5 PubMed
Arthritis Rheum. 2000 Jan;43(1):22-9 PubMed
Ann Rheum Dis. 2012 Mar;71(3):351-7 PubMed
